Modeling Principle

The Beagle Osteoporosis Model is a SCI gold-standard large-animal pathological model of postmenopausal osteoporosis established by bilateral ovariectomy (OVX) combined with low-calcium and low-fat diet intervention. It accurately recapitulates the complete pathological cascade of postmenopausal osteoporosis induced by estrogen deficiency in clinical women, including rapid systemic bone mass loss, cancellous bone microarchitecture collapse, cortical bone thinning, excessive bone resorption, insufficient compensatory bone formation and elevated risk of fragility fracture. It compensates for experimental defects of rodent animals with remarkable differences from humans in bone size, bone remodeling cycle, cortical/cancellous bone ratio and calcium-phosphorus metabolic regulatory pathways.

The skeletal anatomy, cancellous trabecular arrangement, cortical bone thickness, estrogen-regulated bone metabolism mechanism, RANKL/OPG bone remodeling pathway and intestinal calcium absorption rhythm of young female Beagle dogs are highly homologous to humans. Persistent estrogen deficiency occurs after bilateral ovariectomy, which relieves the inhibitory effect of estrogen on osteoclast differentiation. The expression of RANKL is significantly upregulated while OPG secretion decreases, and the imbalance of RANKL/OPG ratio drives massive proliferation and activation of osteoclasts. Meanwhile, osteoblast activity increases compensatorily but cannot offset the rate of bone resorption, leading to continuously elevated bone turnover rate. Combined with low-calcium diet to reduce intestinal calcium intake, negative calcium balance is further aggravated, accelerating thinning, fracture and reduction of trabeculae in lumbar vertebrae, distal femur and proximal tibia, increased cortical bone porosity and decreased thickness, and gradually forming typical osteoporotic phenotype with low bone mass and damaged bone microarchitecture. This model fully recapitulates the classic pathogenic cascade of human postmenopausal osteoporosis: estrogen deficiency-RANKL/OPG imbalance-excessive osteoclast activation-trabecular degradation-reduced bone mass-increased bone fragility.

Beagle dogs possess sufficient size of weight-bearing limbs and lumbar vertebrae with bone remodeling cycle close to humans. The progression of osteoporotic lesions is slow with minimal individual dispersion and no spontaneous bone metabolic disorders. It can clearly distinguish three-stage phenotypes including early stage of elevated bone turnover after operation, middle stage of rapid bone mass loss and terminal stage of stable osteoporosis formation, serving as a standardized large-animal gold-standard model for translational research on postmenopausal osteoporosis pathogenesis, anti-osteoporotic drugs, calcium absorption regulatory preparations, bone repair implant materials and fracture prevention and treatment.

Modeling Success Criteria

Macroscopic Bone Mineral Density and Gross Skeletal Phenotype

The lumbar and femoral bone mineral density of sham control group maintained a stable high level, the cancellous bone of distal femur was full with dense trabeculae and hard bone texture. At Week 12 terminal point, the lumbar and femoral bone mineral density of model group decreased significantly compared with sham group. Gross anatomical observation showed sparse cancellous bone, expanded medullary cavity and thinned cortical bone in distal femur with elevated bone fragility. The macroscopic low bone mass phenotype was typical with extremely significant inter-group difference, confirming preliminary successful construction of osteoporosis model.

Quantitative Biochemical Gold-Standard Indexes of Serum Bone Metabolism and Endocrine

Serum E2 estrogen level of model group was extremely significantly lower than sham group; bone resorption marker CTX-Ⅰ increased sharply while bone formation marker OC rose slightly compensatorily; serum calcium decreased and PTH elevated secondarily; RANKL expression was upregulated while OPG downregulated with remarkably elevated RANKL/OPG ratio, fully matching the core biochemical diagnostic characteristics of postmenopausal osteoporosis: estrogen deficiency, excessive bone resorption, negative calcium balance and RANKL/OPG imbalance.

Bone Micro-CT and Histopathological Characteristics

Combined Micro-CT, HE, Goldner and TRAP staining of distal femoral bone tissues showed characteristic temporal pathological changes of osteoporosis:

1. Early stage at Week 4 after modeling: mild trabecular thinning, slightly increased number of TRAP-positive osteoclasts and mild decline of bone mineral density;
2. Middle progressive stage at Week 8 after modeling: reduced trabecular number, enlarged trabecular separation, elevated cortical bone porosity and massive osteoclast aggregation on trabecular surface;
3. Terminal stage at Week 12 after modeling: massive fractured and sparse incomplete trabeculae, significantly reduced trabecular thickness and number, sharply increased trabecular separation, obviously thinned and porous cortical bone, remarkably increased number of TRAP osteoclasts, which perfectly recapitulates graded characteristics of bone microarchitecture destruction in human postmenopausal osteoporosis.

Core Estrogen-Regulated Bone Remodeling Pathway Indexes

The estrogen-mediated osteogenic protective pathway of model group was inhibited, and NF-κB osteoclast differentiation pathway was persistently activated. Imbalanced RANKL/OPG ratio drove excessive osteoclast proliferation, and bone resorption activity was far higher than bone formation. Downregulation of intestinal calcium transport-related proteins aggravated negative calcium balance, which accurately conforms to the complete pathogenic mechanism induced by OVX combined with low-calcium diet: estrogen deficiency-insufficient calcium absorption-RANKL/OPG imbalance-excessive osteoclast activity-trabecular degradation-osteoporosis, serving as core academic criterion for confirming successful modeling.

Model Advantages

This model is a well-recognized exclusive large-animal gold-standard model for OVX-induced postmenopausal osteoporosis in orthopedic metabolism SCI field. 12-week compound intervention of surgery combined with low-calcium diet stably constructs estrogen-deficient osteoporosis with low bone mass and damaged bone microarchitecture highly homologous to humans. The bone size, bone remodeling cycle, estradiol-regulated bone metabolism and calcium absorption pathway of Beagle dogs are highly close to human body, with uniform bone loss gradient, extremely low intra-group data dispersion and far higher reproducibility than rodents. The modeling mechanism accurately simulates dual pathogenic inducing factors of postmenopausal estrogen decline combined with insufficient dietary calcium intake in women, without single injury deviation caused by simple drugs or glucocorticoid induction. Multi-dimensional detections including bone mineral density scanning, Micro-CT microarchitecture quantification, bone histopathology and systemic bone turnover markers can be carried out synchronously. It is suitable for preclinical large-animal pharmacodynamic evaluation of oral anti-osteoporotic drugs, bisphosphonate preparations, calcium/vitamin D supplements, bone regeneration implant materials and fracture prevention schemes. Sufficient multiple skeletal tissue samples can be obtained from single animal with high clinical transformation credibility and high recognition in high-score SCI journals of orthopedics, bone metabolism and endocrinology, suitable for National Natural Science Foundation, master/doctor project opening, graduation thesis of orthopedics/endocrinology and translational medical research of osteoporosis regenerative repair.

Research Applications

The Beagle Osteoporosis Model is corely applied to basic research on estrogen deficiency-mediated RANKL/OPG imbalance, excessive osteoclast activation, trabecular degradation and loss, intestinal calcium absorption disorder and cortical bone micropore formation. It is specially used for screening and evaluating oral anti-osteoporotic small molecules, bisphosphonates, plant active extracts, calcium-vitamin D compound preparations and bone tissue engineering implant materials with effects of inhibiting osteoclast differentiation, reducing bone resorption, promoting osteogenic mineralization, improving intestinal calcium absorption, ameliorating bone microarchitecture and elevating bone mineral density. It is widely adopted for excavation of pathogenic endocrine targets of postmenopausal osteoporosis, elucidation of estrogen-bone remodeling regulatory network and large-animal preclinical in-vivo pharmacodynamic verification of anti-osteoporotic drugs and implant materials, serving as a scarce and essential standardized large-animal gold-standard model in the fields of bone metabolism endocrinology, orthopedic regenerative repair and geriatric osteopathy pharmacology.

beagle dog ovariectomized osteoporosis model，bone mass loss，bone microarchitecture deterioration，bone turnover disorder，anti-osteoporotic drug preclinical evaluation